Aberrant expression of AKR1B10 has been detected in multiple solid tumors such as hepatocellular cancer [8], lung cancer [9], breast cancer [10] and pancreatic cancer [11], and strongly associated with prognosis [12–15], and downregulated in malignancies of the digestive tract, such as gastric cancer and CRC [15, 16]. Here, AKR1B10 is linked to colorectal carcinoma.